Cargando…

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication

The combination of vonoprazan (VPZ) and amoxicillin (VA therapy) has been shown to achieve acceptable eradication rates for Helicobacter pylori (H. pylori). Herein, our aim was to explore the short-term effect of VA therapy on the gut microbiota and short-chain fatty acids (SCFAs) using human fecal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yi, Xu, Xin, Ouyang, Yao-Bin, He, Cong, Li, Nian-Shuang, Xie, Chuan, Peng, Chao, Zhu, Zhen-Hua, Shu, Xu, Xie, Yong, Lu, Nong-Hua, Zhu, Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201212/ https://www.ncbi.nlm.nih.gov/pubmed/35719338 http://dx.doi.org/10.3389/fcimb.2022.881968

Ejemplares similares

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study
por: Hu, Yi, et al.
Publicado: (2023)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

Efficacy of Vonoprazan for Helicobacter pylori Eradication
por: Kiyotoki, Shu, et al.
Publicado: (2019)

Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis
por: Zhang, Wen-Lin, et al.
Publicado: (2023)

The efficacy and safety of vonoprazan–amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis
por: Feng, Jia-Hui, et al.
Publicado: (2023)

The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study
por: Lin, Yimin, et al.
Publicado: (2022)

Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Düzenli, Tolga, et al.
Publicado: (2023)

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori
por: Yang, Faming, et al.
Publicado: (2023)

Vonoprazan and high‐dose amoxicillin dual therapy for Helicobacter pylori first‐line eradication: A single‐arm, interventional study
por: Sue, Soichiro, et al.
Publicado: (2022)

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
por: Sugimoto, Mitsushige, et al.
Publicado: (2019)

RE: Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

The management of Helicobacter pylori infection and prevention and control of gastric cancer in China
por: Hu, Yi, et al.
Publicado: (2022)

Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial
por: Zuberi, Bader Faiyaz, et al.
Publicado: (2022)

An Overview of Autophagy in Helicobacter pylori Infection and Related Gastric Cancer
por: Yang, Yihan, et al.
Publicado: (2022)

A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of Helicobacter pylori: A Non-Inferiority Clinical Trial
por: Li, Juan, et al.
Publicado: (2023)

Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
por: Kusunoki, Maho, et al.
Publicado: (2019)

The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori
por: Zhang, Zinan, et al.
Publicado: (2023)

The impact of Helicobacter pylori eradication with vonoprazan-amoxicillin dual therapy combined with probiotics on oral microbiota: a randomized double-blind placebo-controlled trial
por: Peng, Ruolin, et al.
Publicado: (2023)

Vonoprazan-Associated Gastric Mucosal Redness in Non-Helicobacter pylori-Infected and Helicobacter pylori-Eradicated Stomach
por: Kubo, Kimitoshi, et al.
Publicado: (2021)

Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis
por: Wang, Yue, et al.
Publicado: (2023)

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
por: Sakurai, Kouichi, et al.
Publicado: (2017)

The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis
por: Liu, Ligang, et al.
Publicado: (2023)

Helicobacter pylori infection altered gastric microbiota in patients with chronic gastritis
por: Hua, Zhaolai, et al.
Publicado: (2023)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

Effect of Helicobacter Pylori Eradication on Human Gastric Microbiota: A Systematic Review and Meta-Analysis
por: Guo, Yang, et al.
Publicado: (2022)

Editorial: The interactions between gastrointestinal microbiota and Helicobacter pylori in diseases
por: Hu, Yi, et al.
Publicado: (2022)

14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial
por: Yang, Qinyu, et al.
Publicado: (2023)

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
por: Sue, Soichiro, et al.
Publicado: (2017)

Refractory Helicobacter pylori infection and the gastric microbiota
por: Liu, Dongsheng, et al.
Publicado: (2022)

Effects of Helicobacter pylori eradication on esophageal motility, esophageal acid exposure, and gastroesophageal reflux disease symptoms
por: Zhao, Tong, et al.
Publicado: (2023)

Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant Helicobacter pylori
por: Sue, Soichiro, et al.
Publicado: (2023)

Discovery and Validation of Novel Methylation Markers in Helicobacter pylori-Associated Gastric Cancer
por: Wang, Huan, et al.
Publicado: (2021)

Characteristics of Helicobacter pylori Heteroresistance in Gastric Biopsies and Its Clinical Relevance
por: Wang, You-hua, et al.
Publicado: (2022)

Focusing on Helicobacter pylori infection in the elderly
por: Gong, Hang, et al.
Publicado: (2023)

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)

Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Kashani, Negin, et al.
Publicado: (2018)

Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China
por: Gao, Wen, et al.
Publicado: (2022)

Relationship between Helicobacter pylori infection and gastrointestinal microecology
por: Xu, Wenting, et al.
Publicado: (2022)

Efficacy and safety of vonoprazan–amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial
por: Wang, Xiaolei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_55ogj717lohk6rpu8q1n07hcv8